查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
欧洲基因融合测试市场-分析与预测（2023-2033）
市场调查报告书
商品编码
1419003

欧洲基因融合测试市场-分析与预测（2023-2033）

Europe Gene Fusion Testing Market: Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 83 Pages | 商品交期: 1-5个工作天内

价格

2023年欧洲基因融合检测市场规模为7,140万美元，预计到2033年将达到2.482亿美元，2023-2033年预测期间复合年增长率为13.27%，预计将成为。

由于标靶治疗的进步，基因融合测试的使用不断增加，预计基因融合测试市场将会成长。

主要市场统计数据
预测期 2023-2033
2023年评估 7140万美元
2033年预测 2.482 亿美元
复合年增长率 13.27%

欧洲基因融合测试市场正在经历显着的成长和演变。这背后有几个因素，包括该地区越来越注重开发精准医学和标靶治疗。基因融合测试可识别导致特定疾病的基因变化，并在针对个别患者制定治疗方案方面发挥至关重要的作用。欧洲对医疗保健创新和研究的承诺正在推动基因融合测试技术的进步，使其更容易获得和准确。此外，该地区强大的製药和生物技术行业正在推动对这些测试的需求，因为他们寻求开发新的疗法。

此外，研究机构和产业相关人员之间的监管支持和合作也有助于市场扩张。随着欧洲继续关注个人化医疗和分子诊断，该地区的基因融合检测市场预计将持续成长和创新。

该报告考察了欧洲基因融合测试市场，并提供了市场概述、按适应症和国家分類的趋势以及进入市场的公司概况。

目录

执行摘要

第一章 市场范围

第二章调查方法

第三章市场概况

  • 基因融合检测简介
  • 相关人员的问卷答复

第四章 行业展望

  • 监管状况
    • 欧洲法律要求和框架

第五章 基因融合测试市场（按地区），金额（百万美元），2022-2033

  • 概述
  • 欧洲
    • 欧洲基因融合检测市场，依指标划分
    • 欧洲基因融合测试市场（按国家）

第六章市场－竞争基准化分析与公司概况

  • 概述
  • Biocartis
  • F. Hoffmann-La Roche Ltd
  • OncoDNA
  • OncoDNA
Product Code: BHP1840SS

“The Europe Gene Fusion Testing Market Expected to Reach $248.2 Million by 2033.”

Introduction to Europe Gene Fusion Testing Market

The Europe gene fusion testing market was valued at $71.4 million in 2023 and is anticipated to reach $248.2 million by 2033, witnessing a CAGR of 13.27% during the forecast period 2023-2033. The gene fusion testing market is anticipated to experience growth due to the increasing use of gene fusion testing for the advancement of targeted therapies.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$71.4 Million
2033 Forecast$248.2 Million
CAGR13.27%

Market Introduction

The gene fusion testing market in Europe is experiencing significant growth and evolution. This can be attributed to several factors, including the region's increasing focus on precision medicine and the development of targeted therapies. Gene fusion testing, which involves identifying genetic alterations that drive certain diseases, plays a pivotal role in tailoring treatments to individual patients. Europe's commitment to healthcare innovation and research is fostering advancements in gene fusion testing technologies, making them more accessible and accurate. Additionally, the region's strong pharmaceutical and biotechnology sectors are driving demand for these tests as they seek to develop novel therapeutics.

Furthermore, regulatory support and collaborations between research institutions and industry players are contributing to market expansion. As Europe continues to emphasize personalized medicine and molecular diagnostics, the gene fusion testing market in the region is poised for continued growth and innovation.

Market Segmentation:

Segmentation 1: by Indication

  • Solid Tumors
  • Hematological Malignancies

Segmentation 2: by Country

  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The Europe gene fusion testing market (by indication) has been segmented into solid tumors and hematological malignancies. Moreover, the study provides the reader with a detailed understanding of the different indication of gene fusion testing in solid tumors.

Growth/Marketing Strategy: Gene fusion testing is a molecular diagnostic method employed to identify and analyze distinct genetic alterations in cancer cells. It arises when two distinct genes, typically from different chromosomes, abnormally join together, giving rise to a hybrid gene that generates a unique protein with modified functions.

Competitive Strategy: Key players in the Europe gene fusion testing market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the Europe gene fusion testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

  • Biocartis
  • F. Hoffmann-La Roche Ltd.
  • OncoDNA
  • QIAGEN N.V.

Table of Contents

Executive Summary

1. Market Scope

  • 1.1. Key Questions Answered in the Report

2. Research Methodology

3. Market Overview

  • 3.1. Introduction to Gene Fusion Testing
    • 3.1.1. Different Technologies for Gene Fusion Testing
    • 3.1.2. Advantages and Limitations of Gene Fusion Testing
    • 3.1.3. Current Market Size and Future Growth Potential, $Million, 2022-2033
      • 3.1.3.1. Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion vs. Other Gene Fusions
    • 3.1.4. Role of Artificial Intelligence (AI) and Machine Learning (ML) in Gene Fusion Testing
    • 3.1.5. Reimbursement Landscape
  • 3.2. Stakeholder's Survey Response
    • 3.2.1. Awareness of Gene Fusion Testing
    • 3.2.2. Familiarity with the NGS Offerings of the Following Companies
    • 3.2.3. Adoption and Barriers for Gene Fusion Testing

4. Industry Outlook

  • 4.1. Regulatory Landscape
    • 4.1.1. Legal Requirements and Frameworks in Europe

5. Gene Fusion Testing Market (by Region), Value ($Million), 2022-2033

  • 5.1. Overview
  • 5.2. Europe
    • 5.2.1. Europe Gene Fusion Testing Market, by Indication
    • 5.2.2. Europe Gene Fusion Testing Market (by Country)
      • 5.2.2.1. Germany
        • 5.2.2.1.1. Germany Gene Fusion Testing Market (by Indication)
      • 5.2.2.2. France
        • 5.2.2.2.1. France Gene Fusion Testing Market (by Indication)
      • 5.2.2.3. U.K.
        • 5.2.2.3.1. U.K. Gene Fusion Testing Market (by Indication)
      • 5.2.2.4. Italy
        • 5.2.2.4.1. Italy Gene Fusion Testing Market (by Indication)
      • 5.2.2.5. Spain
        • 5.2.2.5.1. Spain Gene Fusion Testing Market (by Indication)
      • 5.2.2.6. Netherlands
        • 5.2.2.6.1. Netherlands Gene Fusion Testing Market (by Indication)
      • 5.2.2.7. Rest-of-Europe
        • 5.2.2.7.1. Rest-of-Europe Gene Fusion Testing Market (by Indication)

6. Markets - Competitive Benchmarking & Company Profiles

  • 6.1. Overview
  • 6.2. Biocartis
    • 6.2.1. Company Overview
    • 6.2.2. Role of Biocartis in the Gene Fusion Testing Market
    • 6.2.3. Key Competitors
    • 6.2.4. Recent Developments
    • 6.2.5. Financials
    • 6.2.6. Key Insights about the Financial Health of the Company
    • 6.2.7. Analyst Perspective
  • 6.3. F. Hoffmann-La Roche Ltd.
    • 6.3.1. Company Overview
    • 6.3.2. Role of F. Hoffmann-La Roche Ltd in the Gene Fusion Testing Market
    • 6.3.3. Key Competitors
    • 6.3.4. Recent Developments
    • 6.3.5. Financials
    • 6.3.6. Key Insights about the Financial Health of the Company
    • 6.3.7. Analyst Perspective
  • 6.4. OncoDNA
    • 6.4.1. Company Overview
    • 6.4.2. Role of OncoDNA in the Gene Fusion Testing Market
    • 6.4.3. Key Competitors
    • 6.4.4. Recent Developments
    • 6.4.5. Analyst Perspective
  • 6.5. QIAGEN N.V.
    • 6.5.1. Company Overview
    • 6.5.2. Role of QIAGEN N.V. in the Gene Fusion Testing Market
    • 6.5.3. Key Competitors
    • 6.5.4. Recent Developments
    • 6.5.5. Financials
    • 6.5.6. Key Insights about the Financial Health of the Company
    • 6.5.7. Analyst Perspective

List of Figures

  • Figure 1: Europe Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 2: Europe Gene Fusion Testing Market: Drivers, Restraints, and Opportunities
  • Figure 3: Europe Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 4: Europe Gene Fusion Testing Market: Research Methodology
  • Figure 5: Primary Research Methodology
  • Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 7: Top-Down Approach (Segment-Wise Analysis)
  • Figure 8: Different Approaches to Study Gene Fusion
  • Figure 9: Different Techniques Used in Gene Fusion Testing
  • Figure 10: Europe Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 11: Artificial Intelligence and Machine Learning in Gene Fusion Testing
  • Figure 12: SOPHiA DDM RNAtarget Technology Workflow
  • Figure 13: Awareness to the Concept of Gene Fusion Testing
  • Figure 14: Familarity with NGS Offerings by Key Market Players for Gene Fusion Testing
  • Figure 15: Perceived Importance of Key Drivers to Improve Gene Fusion Testing Adoption
  • Figure 16: Agreement Level with Key Barriers to Gene Fusion Testing Adoption
  • Figure 17: Europe In Vitro Diagnostic Devices Regulation Regulatory Process
  • Figure 18: Gene Fusion Testing Market (by Region), $Million, 2022 and 2033
  • Figure 19: Europe Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 20: Europe: Market Dynamics
  • Figure 21: Europe Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 22: Europe Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
  • Figure 23: Germany Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 24: Germany Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 25: Germany Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
  • Figure 26: France Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 27: France Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 28: France Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
  • Figure 29: U.K. Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 30: U.K. Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 31: U.K. Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
  • Figure 32: Italy Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 33: Italy Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 34: Italy Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
  • Figure 35: Spain Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 36: Spain Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 37: Spain Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
  • Figure 38: Netherlands Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 39: Netherlands Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 40: Netherlands Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
  • Figure 41: Rest-of-Europe Gene Fusion Testing Market, $Million, 2022-2033
  • Figure 42: Rest-of-Europe Gene Fusion Testing Market (by Indication), $Million, 2022-2033
  • Figure 43: Rest-of-Europe Gene Fusion Testing Market (by Solid Tumors), $Million, 2022-2033
  • Figure 44: Gene Fusion Testing Market (by Total Number of Companies Profiled)
  • Figure 45: Biocartis: Product Portfolio
  • Figure 46: Biocartis: Overall Financials, $Million, 2020-2022
  • Figure 47: Biocartis: Revenue (by Segment), $Million, 2020-2022
  • Figure 48: Biocartis: Revenue (by Region), $Million, 2020-2022
  • Figure 49: Biocartis: R&D Expenditure, $Million, 2020-2022
  • Figure 50: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 51: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 52: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
  • Figure 53: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
  • Figure 54: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
  • Figure 55: OncoDNA: Product Portfolio
  • Figure 56: QIAGEN N.V.: Product Portfolio
  • Figure 57: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
  • Figure 58: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
  • Figure 59: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
  • Figure 60: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022

List of Tables

  • Table 1: Europe Gene Fusion Testing Market, Impact Analysis
  • Table 2: Key Questions Answered in the Report
  • Table 3: Advantages of Gene Fusion Testing
  • Table 4: Limitations of Gene Fusion Testing
  • Table 5: NTRK Gene Fusion in Different Types of Cancer
  • Table 6: Different Types of Gene Fusion
  • Table 7: Gene Fusion Testing Market: Regulatory Scenario
  • Table 8: NTRK Test Rate Across Several Europen Countries